SG11202109152UA - Hyaluronan conjugates and uses thereof - Google Patents
Hyaluronan conjugates and uses thereofInfo
- Publication number
- SG11202109152UA SG11202109152UA SG11202109152UA SG11202109152UA SG11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA SG 11202109152U A SG11202109152U A SG 11202109152UA
- Authority
- SG
- Singapore
- Prior art keywords
- hyaluronan conjugates
- hyaluronan
- conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962856714P | 2019-06-03 | 2019-06-03 | |
PCT/US2020/035780 WO2020247407A1 (en) | 2019-06-03 | 2020-06-02 | Hyaluronan conjugates and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109152UA true SG11202109152UA (en) | 2021-12-30 |
Family
ID=73550112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109152UA SG11202109152UA (en) | 2019-06-03 | 2020-06-02 | Hyaluronan conjugates and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US11524079B2 (en) |
EP (2) | EP3976019A4 (en) |
JP (1) | JP7275320B2 (en) |
KR (1) | KR20210151062A (en) |
CN (1) | CN113660933B (en) |
AU (1) | AU2020288834B2 (en) |
BR (1) | BR112021019113A2 (en) |
CA (1) | CA3133671C (en) |
CO (1) | CO2021012240A2 (en) |
EA (1) | EA202192225A1 (en) |
IL (1) | IL287917A (en) |
MX (1) | MX2021013140A (en) |
SG (1) | SG11202109152UA (en) |
TW (2) | TWI737330B (en) |
WO (2) | WO2020247407A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024080183A1 (en) * | 2022-10-14 | 2024-04-18 | 国立大学法人東海国立大学機構 | Glycan complex, drug carrier, and drug delivery system |
CN115970046B (en) * | 2022-12-02 | 2024-04-26 | 南京工业大学 | Application of multifunctional hydrogel in preparation of medicine for treating diabetes wound |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087552A2 (en) * | 2001-05-01 | 2002-11-07 | Mcgill University | Androgen-mediated neuroprotection and uses thereof |
AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
ES2447025T3 (en) * | 2005-07-12 | 2014-03-11 | Ampio Pharmaceuticals, Inc. | Methods and products for the treatment of diseases |
CN103784960A (en) * | 2005-07-27 | 2014-05-14 | 阿尔卡米亚肿瘤学股份有限公司 | Therapeutic protocols using hyaluronan |
KR100806088B1 (en) | 2007-08-09 | 2008-02-21 | 고려대학교 산학협력단 | Compositions for delivering nucleic acids using cationic polymer conjugates consisting of hyaluronic acid and polyethylenimine |
WO2011148116A2 (en) | 2010-05-27 | 2011-12-01 | Laboratoire Idenov | Modified hyaluronic acid, method for manufacturing same and uses thereof |
US8895069B2 (en) | 2011-05-16 | 2014-11-25 | Postech Academy-Industry Foundation | Drug delivery system using hyaluronic acid-peptide conjugate micelle |
US20130116411A1 (en) | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Methods of making hyaluronic acid/collagen compositions |
JP6275044B2 (en) * | 2012-09-05 | 2018-02-07 | 中外製薬株式会社 | Hyaluronic acid derivatives with amino acid and steryl groups introduced |
MX2015011847A (en) | 2013-03-08 | 2016-01-08 | Allergan Inc | Antibiotic conjugates linked with steroid drugs. |
US10000582B2 (en) * | 2013-04-02 | 2018-06-19 | The Regents Of The University Of California | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof |
US9572832B2 (en) | 2013-08-29 | 2017-02-21 | Holy Stone Healthcare Co., Ltd. | Compound of glycosaminoglycan and its fabrication method as well as application |
WO2016007856A1 (en) * | 2014-07-10 | 2016-01-14 | Academia Sinica | Multi-drug delivery system and uses thereof |
US20160279108A1 (en) * | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
KR101818705B1 (en) | 2015-07-20 | 2018-01-16 | 포항공과대학교 산학협력단 | Cross-linked hyaluronic acid hydrogel encapsulating therapeutic drugs and uses thereof |
WO2017120193A1 (en) | 2016-01-04 | 2017-07-13 | University Of Kansas | Drug delivery compositions and methods |
CZ2016826A3 (en) | 2016-12-22 | 2018-07-04 | Contipro A.S. | A medicinal agent with a carrier based on hyaluronan and/or its derivatives, a method of the manufacture and use |
TWI626043B (en) * | 2017-06-13 | 2018-06-11 | 心悅生醫股份有限公司 | Use of Lithium Benzoate for Treating Central Nervous System Disorders |
TW201912152A (en) * | 2017-08-30 | 2019-04-01 | 保羅 L 曼弗雷蒂 | Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof |
-
2020
- 2020-06-02 KR KR1020217029017A patent/KR20210151062A/en not_active Application Discontinuation
- 2020-06-02 BR BR112021019113A patent/BR112021019113A2/en unknown
- 2020-06-02 WO PCT/US2020/035780 patent/WO2020247407A1/en active Application Filing
- 2020-06-02 EP EP20818542.1A patent/EP3976019A4/en active Pending
- 2020-06-02 EA EA202192225A patent/EA202192225A1/en unknown
- 2020-06-02 SG SG11202109152UA patent/SG11202109152UA/en unknown
- 2020-06-02 CN CN202080016386.9A patent/CN113660933B/en active Active
- 2020-06-02 CA CA3133671A patent/CA3133671C/en active Active
- 2020-06-02 JP JP2021568410A patent/JP7275320B2/en active Active
- 2020-06-02 US US16/891,020 patent/US11524079B2/en active Active
- 2020-06-02 AU AU2020288834A patent/AU2020288834B2/en active Active
- 2020-06-02 MX MX2021013140A patent/MX2021013140A/en unknown
- 2020-06-03 TW TW109118583A patent/TWI737330B/en active
- 2020-12-10 WO PCT/US2020/064293 patent/WO2021247076A1/en unknown
- 2020-12-10 EP EP20938836.2A patent/EP4157256A1/en active Pending
- 2020-12-11 TW TW109143747A patent/TWI817065B/en active
-
2021
- 2021-09-17 CO CONC2021/0012240A patent/CO2021012240A2/en unknown
- 2021-11-08 IL IL287917A patent/IL287917A/en unknown
-
2022
- 2022-11-02 US US17/979,450 patent/US20230080473A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200376132A1 (en) | 2020-12-03 |
CA3133671C (en) | 2023-12-19 |
AU2020288834B2 (en) | 2022-12-22 |
JP2022539652A (en) | 2022-09-13 |
CA3133671A1 (en) | 2020-12-10 |
MX2021013140A (en) | 2021-12-10 |
TW202110456A (en) | 2021-03-16 |
EP3976019A1 (en) | 2022-04-06 |
EP3976019A4 (en) | 2023-03-01 |
KR20210151062A (en) | 2021-12-13 |
CO2021012240A2 (en) | 2021-09-30 |
AU2020288834A1 (en) | 2021-09-16 |
TWI817065B (en) | 2023-10-01 |
CN113660933A (en) | 2021-11-16 |
WO2020247407A1 (en) | 2020-12-10 |
WO2021247076A1 (en) | 2021-12-09 |
BR112021019113A2 (en) | 2021-12-14 |
TW202146051A (en) | 2021-12-16 |
JP7275320B2 (en) | 2023-05-17 |
US11524079B2 (en) | 2022-12-13 |
EA202192225A1 (en) | 2022-03-15 |
EP4157256A1 (en) | 2023-04-05 |
IL287917A (en) | 2022-01-01 |
CN113660933B (en) | 2023-12-01 |
TWI737330B (en) | 2021-08-21 |
US20230080473A1 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3732185A4 (en) | Conjugates and preparation and use thereof | |
IL286291A (en) | Compounds and conjugates thereof | |
LT3579883T (en) | Pyrrolobenzodiazepine-antibody conjugates | |
HUE054689T2 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
IL287391A (en) | Amatoxin antibody-drug conjugates and uses thereof | |
GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
EP3645041A4 (en) | Anti-mertk agonistic antibody-drug conjugates and uses thereof | |
SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
IL275208A (en) | Hsp90-targeting conjugates and formulations thereof | |
AU2016349786B2 (en) | Anti-CD3-folate conjugates and their uses | |
IL287917A (en) | Hyaluronan conjugates and uses thereof | |
IL291312A (en) | Anti-ptcra antibody-drug conjugates and uses thereof | |
GB201820626D0 (en) | Conjugates | |
EP3700533A4 (en) | Sstr-targeted conjugates and formulations thereof | |
GB201818562D0 (en) | Pyrrolobenzodiazephones and conjugates thereof | |
GB201903535D0 (en) | Compounds and conjugates | |
GB201903541D0 (en) | Compounds and conjugates | |
IL288681A (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201906997D0 (en) | Conjugates | |
GB201900735D0 (en) | Conjugates | |
GB201712101D0 (en) | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | |
GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201721290D0 (en) | Conjugates | |
GB201719906D0 (en) | Pyrrolobenzodiazepine-antibody conjugates |